NasdaqCM:VKTXBiotechs
Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity Trials - And What's Next
In recent weeks, Viking Therapeutics has pushed its obesity candidate VK2735 further into late-stage development, completing or nearly completing enrollment for its Phase 3 VANQUISH trials and preparing an oral Phase 3 program after positive Phase 2 data and FDA feedback.
This acceleration across both injectable and oral formulations of VK2735 strengthens the company’s position in the growing market for flexible obesity treatments and heightens the importance of upcoming clinical readouts...